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OBJECTIVES We tested whether acute hormone therapy reduces ambulatory electrocardiographic ischemia
in postmenopausal (PMP) women with unstable angina (UA).
BACKGROUND Endothelial dysfunction contributes to the pathophysiology of UA. Acute estrogen admin-
istration improves endothelial function in PMP women with coronary artery disease and
increases coronary artery blood flow.
METHODS Two hundred ninety-three PMP women with UA (mean age 69.7 years), treated with
standard anti-ischemic therapy, were enrolled within 24 h of symptom onset. In a
double-blind fashion, subjects were randomized to receive intravenous followed by oral
conjugated estrogen for 21 days, intravenous estrogen followed by oral conjugated estrogen
plus medroxyprogesterone for 21 days or placebo. The primary end point was the number of
ambulatory electrocardiographic ischemic events over the first 48 h. Clinical events were also
determined over six months of follow-up.
RESULTS Electrocardiographic ischemia did not differ among the three randomized groups. The mean
number of ischemic events per patient over 48 h was 0.74 for estrogen, 0.86 for estrogen plus
progesterone and 0.74 for the placebo groups (p  0.87). The percentage of patients with
ischemic events and the mean duration of ischemia did not differ between hormone- and
placebo-treated patients. In-hospital and six-month rates of adverse clinical events were also
similar among the three randomized groups.
CONCLUSIONS Acute hormone therapy does not reduce ischemia in PMP women with UA when added to
standard anti-ischemic therapy. (J Am Coll Cardiol 2002;39:231–7) © 2002 by the
American College of Cardiology
Coronary artery disease (CAD) is the leading cause of
morbidity and mortality in women over the age of 50 years
(1). Acute coronary syndromes (ACS) present differently in
men and women. Men more often present with ST-
segment elevation myocardial infarction (MI) and suffer
fewer infarct complications, including heart failure and
cardiogenic shock (2,3). Women with ACS are older, have
greater comorbidity and more often present with unstable
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angina (UA) (2). Despite older age and greater number of
risk factors compared with men, up to 30% of women
compared with 14% of men presenting with UA have no
significant CAD on coronary angiography (2), suggesting
that the pathophysiology of ischemic chest pain in women
may be more diverse than it is in men (4).
In women without epicardial stenoses, small vessel CAD
and endothelial dysfunction may cause coronary vasocon-
striction, reduced coronary blood flow and ischemic chest
pain (5). In the setting of atherosclerotic plaque rupture,
coronary artery vasoconstriction occurs in response to sero-
tonin and thromboxane A2 released from activated platelets
(6,7). Estrogen could, theoretically, reduce ischemia in both
circumstances. Acute administration of estrogen causes
coronary vasodilation and reverses endothelial dysfunction
within minutes in postmenopausal (PMP) women with
CAD (8–12). The addition of progesterone to estrogen,
commonly utilized in many PMP women, may, however,
attenuate the beneficial effects of estrogen on endothelial
function and coronary vasodilation (13,14).
To assess the possible benefit of short-term estrogen
therapy for PMP women with UA, we conducted a ran-
domized, double-blind, placebo-controlled trial comparing
the effects of conjugated equine estrogen (E) alone, E plus
medroxyprogesterone (MPA) and placebo (PLBO) on am-
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bulatory electrocardiogram (ECG) ischemia, a predictor of
adverse outcomes in patients with ACS (15–17).
METHODS
Patient selection. Postmenopausal women presenting
from July 1995 to September 1999 with an episode of UA
within the prior 24 h were eligible. Postmenopausal status
was defined as last menses 1 year before enrollment,
previous bilateral oophorectomy or previous hysterectomy in
women 55 years of age. Unstable angina was defined as
ischemic pain lasting 10 min with reversible ECG ST-
segment changes or ischemic chest pain in patients with
CAD diagnosed by prior angiography or prior MI in whom
an ECG was not available at the time of chest pain.
We excluded patients with uninterpretable ECG ST
segments (e.g., ventricular paced rhythm, left bundle branch
block), known MI within 24 h of enrollment, cardiogenic
shock, estrogen replacement therapy within one year of
admission or a history of hormone-dependent neoplasia,
liver tumors or deep vein thrombosis. We also excluded
patients with UA scheduled for percutaneous coronary
intervention (PCI) within 24 h of admission to the hospital
or who developed UA within 72 h after a PCI.
The investigational review board at each participating
institution approved the study. Signed, informed consent
was obtained from all patients.
Protocol. Patients received routine anti-ischemic therapy
as determined by their attending physician, including aspi-
rin, unfractionated heparin, beta-blockers and nitrates. Gly-
coprotein (GP) IIb/IIIa inhibitors were available for use
when clinically indicated in the last 55 enrolled patients.
The patient’s attending physician made all decisions con-
cerning cardiac catheterization and revascularization proce-
dures.
Patients were randomized in a double-blind fashion to
one of three 21-day courses of study drug. Each patient
received a single intravenous infusion at study entry fol-
lowed by two capsules for 21 days: 1) 1.25 mg of intravenous
E infused over 30 min followed immediately by 1.25
mg/day of oral E plus 2.5 mg/day of oral MPA; 2) 1.25 mg
of intravenous E followed immediately by 1.25 mg/day of
oral E plus PLBO; and 3) intravenous PLBO followed
immediately by oral PLBO capsules. This dose of E
reversed cold pressor induced coronary vasoconstriction in
11 PMP women (preliminary data) as well as in men (18).
Vital signs were monitored at 10-min intervals from 20 min
before study drug infusion until 30 min after the end of
study drug infusion.
During the first 48 h of the study, continuous ambulatory
ECG monitoring (Oxford MR45 System, Oxford Medical
Inc., Clearwater, Florida) was performed to measure isch-
emic episodes, defined as ST depression 1 mm lasting 1
min. During the hospital stay, investigators performed daily
assessments for symptomatic ischemia, refractory ischemia
(lasting 10 min despite standard therapy), MI (ischemic
pain, ST changes and creatinine kinase2 the upper limit
of normal) and need for revascularization. Patients returned
at 21 days for clinical assessment and 48-h ambulatory ECG
monitoring. Pill counts for patient compliance was deter-
mined at this time. The study drug was discontinued at 21
days, and patients returned approximately 10 to 14 days
later for clinical assessment and 48-h ambulatory ECG
monitoring.
End points. The primary end point of the trial was the
geometric mean number of ischemic episodes per patient for
48 h on the initial ambulatory ECG. Secondary outcomes
included the percent of patients with ambulatory ECG
ischemia and total duration of ischemia during the first 48 h.
Secondary outcomes also included 21-day and 31-day am-
bulatory ECG ischemia, symptomatic ischemia, refractory
ischemia, MI or death during the index hospitalization.
Three-month and six-month outcomes of death, MI and
need for coronary revascularization were determined by
telephone interviews. Outcomes associated with inpatient
admission were confirmed by hospital record review.
Statistical analysis. Patient characteristics are presented as
counts and percentages and compared using the chi-square
for categorical data and t tests for continuous data. Fisher
exact test was used for characteristics with prevalence 5%.
Outcomes were compared using tests of differences for two
proportions for dichotomous data and t tests for continuous
data for the two hormonal therapy groups (E  MPA and
E  PLBO). When no difference between hormone ther-
apy groups was found, the two groups were pooled and the
same comparisons repeated for the pooled hormonal therapy
groups and placebo group data. Analysis of the primary end
point (number of ischemic episodes) was performed using
the transformation log (48·[number of ischemic episodes 
0.5]/h recorded). Outcomes for clinical events were com-
pared with survival analysis. Data are expressed as the
geometric mean and the range because of the nonparametric
distribution of the ambulatory ECG ischemic episodes.
The planned sample size was 117 patients per treatment
group based on a two-sided alpha 0.05 and power 0.80,
assuming a 40% reduction in the number of ischemic
episodes in the hormone therapy group would be clinically
significant. Interim analyses were planned setting the critical
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values according to the method of Fleming et al. (19),
adjusting the final, primary analysis critical value to p 
0.041. For secondary analyses p  0.01 is required for some
evidence of differences and p  0.001 for strong evidence of
differences. The Data and Safety Monitoring Committee
advised terminating the study after a predetermined interim
analysis when 293 patients were enrolled due to a lack of
difference among the three randomized groups at that time
and a decrease in the mean number of ischemic episodes in
all of the groups.
RESULTS
Patient demographics. The study randomized 293 PMP
women with UA: 94 patients received E  MPA, 100
patients received E  PLBO and 99 patients received
PLBO only. Patient demographics are presented in Table 1,
reflecting an older cohort of patients with UA with a high
prevalence of prior CAD and risk factors. On admission
ECG tracing, 3% to 5% of patients had reversible ST-
segment elevation, one-third had new ST-segment depres-
sion and one-fifth had ischemic T-wave changes. Coronary
risk factors and admission ECG patterns were similar
among the three randomized groups. About one in four
patients in each group had pulmonary vascular congestion
on the admission chest radiograph.
The three groups received comparable anti-ischemic
therapy (Table 2). The majority of patients in each random-
ized group received anticoagulation with intravenous hepa-
rin, aspirin, beta-blocker therapy and intravenous, topical or
oral nitroglycerin. Nine patients, evenly distributed among
the three randomized groups, received a GP IIb/IIIa inhib-
itor during the first 48 h of the study.
ECG ischemia during first 48 h. The study drug infusion
was well tolerated. There were no differences in blood
pressure or heart rate between those patients receiving
intravenous estrogen and those receiving placebo. Table 3
shows results of the ambulatory ECGs performed during
the 48 h after study enrollment. The mean number of
ischemic events, the study’s primary outcome variable, did
not differ between patients treated with hormone therapy
(E  MPA and E  PLBO) and with PLBO or between
patients treated with E only compared with the combina-
tion of E and MPA. The percent of patients with ECG
ischemia and the mean ischemic time per 48 h did not
significantly differ between the two hormone therapy groups
or between the patients who received hormone therapy and
placebo. The median number of ischemic events and dura-
tion of ischemia over 48 h was zero in all three groups.
Recurrent symptomatic ischemia during the hospitaliza-
tion did not vary among the three groups. In those patients
who experienced ambulatory ECG ischemia, the majority
had one to three ischemic events over the first 48 h,
although five patients randomized to E  MPA, one
patient randomized to E and three patients randomized to
PLBO experienced 6 ischemic events.
Several predefined subgroups were evaluated for the effect
of study drug on ECG ischemia. In subgroups comprising
patients 70 years of age, African Americans and patients
with diabetes, a prior MI or congestive heart failure, there
were no differences between hormone therapy and placebo
in the number of ischemic episodes, the duration of isch-
emia or percentage of patients with ECG ischemia over the
first 48 h. Patients with transient ST-segment depression on
the admission ECG experienced more ischemic episodes
and represented a greater proportion of patients with ECG
ischemia over the first 48 h than those without admission
ECG ST-segment changes. However, there was no differ-
Table 1. Patient Demographics
Characteristic (n)
E  MPA
(n  94)
E  PLBO
(n  100)
PLBO
(n  99)
p
Value
Age (range, yrs) 69.9 (51–91) 69.7 (48–89) 69.6 (43–93) 0.99
African American 39.4% 31% 34.3% 0.25
ECG changes 64.9% 53.0% 57.6% 0.24
Prior CAD 75.5% 81.0% 80.8% 0.57
Hypertension 75.5% 81.0% 75.8% 0.78
Prior TIA/CVA 16.0% 17.0% 16.2% 0.98
Prior CHF 18.5% 16.0% 29.5% 0.05
Prior MI 47.3% 51.0% 53.5% 0.69
Prior CABG 21.3% 21.0% 27.3% 0.50
Prior PCI 22.8% 33.0% 24.2% 0.23
Diabetes 44.7% 42.0% 47.4% 0.75
Cigarettes (current) 12.9% 13.0% 19.2% 0.32
p value for any difference between the three groups.
CABG  coronary artery bypass grafting; CAD  coronary artery disease;
CHF  congestive heart failure; CVA  cerebral vascular accident; E  conjugated
equine estrogen; ECG  electrocardiogram; MI  myocardial infarction; MPA 
medroxyprogesterone; PCI  percutaneous coronary intervention; PLBO  placebo;
TIA  transient ischemic attack.
Table 2. Anti-Ischemic Medications
Medication E  MPA E  PLBO PLBO p Value
Heparin 85.1% 78.8% 76.8% 0.32
Aspirin 92.6% 92.0% 98.0% 0.14
Beta-blocker 76.6% 75.0% 79.6% 0.74
Nitroglycerin 72.3% 74.0% 76.5% 0.76
Abbreviations as in Table 1.
Table 3. First 48-H Ambulatory ECG and Symptomatic Ischemia
Ambulatory ECG E  MPA E  PLBO PLBO p Value
Mean #/48 h (range) 0.86 (0–14) 0.74 (0–7) 0.74 (0–29) 0.87
% with events 14.1 9.8 10.9 0.79
Mean ischemic time (min) (range) 23.5 (0–762) 4.2 (0–222) 8.0 (0–322) 0.81
Symptomatic ischemia 52.1% 39% 42.4% 0.16
p value is the comparison of (E  MPA)  (E  PLBO) vs. PLBO.
Abbreviations as in Table 1.
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ence between hormone therapy and placebo in 48-h ECG
ischemia in this subgroup. Similarly, hormone therapy did
not reduce ECG ischemia in enrolled patients who did not
receive therapy with nitroglycerin during their first 48 h of
hospitalization.
Clinical outcomes during initial hospitalization. During
the index hospitalization for UA, the incidences of death,
MI and need for emergent PCI or coronary artery bypass
grafting did not differ among the three randomized groups
(Fig. 1). The incidences of refractory ischemia during
hospitalization were also similar, 19.8%, 16.3% and 15.4%
for those randomized to EMPA, E PLBO and PLBO
only, respectively.
21-day and 31-day outcomes. A total of 20% of patients
stopped the study drug before 21 days. These 58 patients
were equally distributed across the three randomized
groups. Eighteen of these 58 patients stopped the drug early
due to side effects, and 29 patients stopped the drug early
due to patient or family refusal. Among the 80% who
completed the three weeks of study drug, compliance was
91% by pill count. After three weeks of the study drug, the
mean number of ambulatory ECG ischemic episodes was
small (Table 4), as was the percentage of patients with ECG
ischemia and the mean duration of total ischemia. There
were no differences among the three randomized groups in
day 21 ambulatory ECG ischemia or the proportion of
patients who developed symptomatic ischemia from hospi-
tal discharge to day 21.
Ten days after cessation of the study drug, patients
underwent repeat ambulatory ECG monitoring. The num-
ber of ischemic episodes remained small and did not differ
among the three randomized groups. There was no evidence
of rebound ischemia in any group.
Side effects. Minor side effects were frequent in all groups
during three weeks of the study drug (Table 5). Two
patients in the combined hormone group and two in the E
only group stopped the study drug early due to breast
tenderness. One patient in the E only group stopped the
study drug early due to vaginal bleeding. Additionally, one
patient who received E alone developed a pulmonary em-
bolism (day 2), and one patient who received PLBO
developed a deep vein thrombosis (day 6). Two patients
suffered strokes, one patient in the E  MPA arm (day 5)
and one patient randomized to PLBO (day 9). Both strokes
occurred after coronary artery bypass surgery.
Six-month clinical outcomes. Six-month clinical out-
comes were available for 93% of patients in the entire study
cohort. Kaplan-Meier survival curves for death or nonfatal
MI (Fig. 2) and death, nonfatal MI or need for revascular-
ization (Fig. 3) showed no six-month differences among the
three randomized groups.
DISCUSSION
This randomized, placebo-controlled trial shows that add-
ing E or E plus MPA to standard anti-ischemic therapy
Figure 1. The rates of in-hospital death, myocardial infarction (MI), emergency percutaneous intervention (PCI) and emergency coronary artery bypass
surgery (CABG) are shown for patients randomized to each group. Patients underwent revascularization for recurrent ischemic symptoms or high-risk
presentation. There were no differences in hospital events among the three randomized groups, p  0.91. E  conjugated equine estrogen; MPA 
medroxyprogesterone; PLBO  placebo.
Table 4. Day 21 ECG and Symptomatic Ischemia
Ambulatory ECG E  MPA E  PLBO PLBO p Value
Mean #/48 h (range) 0.71 (0–11) 0.69 (0–5) 0.78 (0–11) 0.27
% with events 8.1% 11.3% 11.9% 0.63
Mean ischemic time (min) (range) 7.5 (0–249) 4.7 (0–151) 10.0 (0–150) 0.40
Symptomatic ischemia 20.3% 26.7% 28.9% 0.43
p value is the comparison of (E  MPA)  (E  PLBO) vs. PLBO.
Abbreviations as in Table 1.
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does not reduce ECG ischemia in PMP women with UA.
Three weeks of hormone therapy did not affect any of the
study’s secondary end points, including in-hospital and
six-month recurrent ischemia, MI, death and need for
revascularization, although the study lacked sufficient power
to determine with confidence these secondary clinical out-
comes.
Estrogen and endothelial dysfunction. Our study was
based on evidence that endothelial dysfunction with subse-
quent impairment in coronary blood flow has an important
pathophysiologic role in ACS (20–22) and that acute
estrogen administration reverses this abnormality (8). Intra-
venous estrogen increases Doppler measured coronary blood
flow and coronary epicardial cross-sectional diameter and
attenuates the vasoconstrictor response to acetylcholine in
women with CAD (8–11). The coronary and brachial artery
vasodilator response in PMP women to acetylcholine plus
estrogen is obliterated with a concomitant infusion of
NG-monomethyl-L-arginine, an inhibitor of nitric oxide
synthase (9,23). These findings suggest that the improve-
ment in endothelial dysfunction with acute estrogen admin-
istration occurs via increased nitric oxide availability. Estro-
gen also causes vasodilation by stimulating the opening of
calcium-activated potassium channels resulting in smooth
muscle relaxation (24). Whether the addition of progester-
one decreases estrogen’s endothelial-dependent vasodilator
effect is controversial (25).
Failure of hormone replacement therapy to reduce am-
bulatory ECG ischemia. There are several potential expla-
nations for the failure of acute hormone replacement ther-
apy to reduce ambulatory ECG ischemia in our study.
Although human endothelial cells and smooth muscle cells
express estrogen receptors (12,26), Losordo et al. (27)
reported that atherosclerotic coronary arteries expressed
fewer estrogen receptors than coronary arteries without
significant atherosclerosis. Furthermore, Post et al. (28)
reported increased rates of estrogen receptor gene promoter
methylation with increasing age, both in nondiseased vessels
and even more so in areas with atherosclerotic plaque.
Increased promoter methylation inactivates estrogen recep-
tor gene transcription. Since women with UA are usually
elderly with significant atherosclerosis, they may be unre-
sponsive to hormone therapy due to lack of the estrogen
receptor. It also is possible that the concurrent use of
nitroglycerin in three-quarters of our patients resulted in
maximal endothelial-independent coronary vasodilation,
thus eliminating any possible benefit of acute estrogen
therapy. These data contrast with the beneficial effects of
acute estrogen therapy reported in small studies of PMP
women with stable CAD on exercise treadmill-induced and
pacing-induced ischemia (29,30). In contrast with the
current cohort with UA, women in these studies were
younger and, due to their stability, may have had less severe
coronary atherosclerosis. Furthermore, the exercise tread-
mill tests and pacing studies were performed in the absence
of any anti-ischemic therapies, which would have been
unethical in our patients with UA.
Other explanations for the observed lack of benefit of
acute hormone therapy are less likely. Although estrogen
therapy induces many genes, these chronic effects are
unlikely to influence 48-h outcomes (12). These more
Figure 2. Six-month rates of death or nonfatal myocardial infarction among the three randomized groups. Event rates did not differ, p  0.97. E 
conjugated equine estrogen; MPA  medroxyprogesterone; PLBO  placebo.
Table 5. Side Effects to Study Drug
Side Effect
E  MPA
(n  94)
E  PLBO
(n  100)
PLBO
(n  99)
p
Value
Flushing 7.4% 7.0% 7.1% 0.99
Headache 12.8% 11.0% 10.1% 0.84
Edema 13.8% 11.0% 9.1% 0.58
Vaginal bleeding 17.0% 10.0% 1.0% 0.001
Breast tenderness 27.7% 23.0% 7.1% 0.001
Mood change 4.3% 5.0% 7.1% 0.67
Any side effect 53.2% 50.0% 44.4% 0.47
Abbreviations as in Table 1.
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chronic effects include estrogen therapy’s mixed effects on
coagulation, increasing mediators of fibrinolysis but also
having prothrombotic effects (31). Estrogen therapy also
increases C-reactive protein (32), an inflammatory marker
that is associated with coronary events in men and women
(33,34).
This trial of acute hormone therapy use adds a previously
unaddressed dimension to the study of estrogen therapy in
ischemia. It also complements two recent randomized trials
evaluating the role of longer-term hormone replacement
therapy in PMP women with chronic stable CAD. The
Heart and Estrogen/progestin Replacement Study (HERS)
showed no difference in the primary end point of coronary
heart disease death plus nonfatal MI in women randomized
to E  MPA compared with PLBO after 4.1 years of
follow-up (35). The Estrogen Replacement and Atheroscle-
rosis trial showed no difference in coronary disease progres-
sion on quantitative angiography in women randomized to
either E, E  MPA or PLBO after 3.2 years of follow-up
(36).
Study limitations. Our power calculations, based on the
existing literature, anticipated an average of one ischemic
event per patient in the placebo group. In actuality, there
were only 0.74 events per patient. The proportion of
patients with any ECG ischemia decreased progressively
during the study, from 16.1% in the first third of patients
enrolled to 11.1% in the second third and 7.5% in the last
third without any discernable change in the demographics
of the population. Similarly, the mean number of ischemic
events per patient for 48 h decreased from 0.86 for the first
third to 0.77 for the second third and 0.71 for the last third
of patients enrolled. These data suggest that aggressive
anti-ischemic therapy has substantially reduced the fre-
quency of ambulatory ECG ischemic events, making am-
bulatory ECG ischemia a less useful research end point.
However, since there was no difference in the number of
ischemic events between patients randomized to hormone
therapy or placebo at any point during the study, it is very
unlikely that enrolling more patients would have yielded
different results. Furthermore, we had a relatively high
dropout rate, which did not affect the primary outcome
variable but reduced our power to assess longer-term out-
comes.
Finally, there was a nonsignificant trend for patients
randomized to E  MPA to experience more ischemia and
recurrent in-hospital angina than patients receiving E alone
or PLBO. This trend supports concerns raised by HERS of
an early increased risk of events in women with CAD
treated with E  MPA (35).
Conclusions. Acute hormone therapy added to standard
anti-ischemic therapy in PMP women with UA does not
reduce the frequency of ECG ischemic events.
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